<DOC>
	<DOC>NCT00730275</DOC>
	<brief_summary>This study will assess the safety, tolerability and pharmacokinetics of sitagliptin in 10 to 17 year old diabetic patients.</brief_summary>
	<brief_title>A Study to Assess the Pharmacokinetics, Safety and Tolerability of Sitagliptin in Adolescents (0431-081)</brief_title>
	<detailed_description />
	<mesh_term>Sitagliptin Phosphate</mesh_term>
	<criteria>Males or females who are 10 17 years of age History of type 2 diabetes Nonsmoker No clinical or laboratory evidence to indicate a diagnosis of type 1 diabetes History of diabetic ketoacidosis History of stroke, chronic seizures or major neurological disorder Consumes alcohol Consume more than 6 servings (1 serving is approximately equivalent to 120 mg of caffeine) of coffee, tea, cola or other beverages containing caffeine per day Unable to swallow tablets Has had surgery, donated or lost 1 unit of blood, or participated in another investigational study within a minimum of 4 weeks prior to starting the study History of multiple and/or severe allergies or has had an allergic reaction to or significant intolerability to prescription or nonprescription drugs or food Currently a regular user of any illicit drugs or has a history of drug or alcohol abuse History of clinically significant endocrine, gastrointestinal, cardiovascular, hematological, hepatic, immunological, renal, respiratory, or genitourinary abnormalities or diseases Has an estimated creatinine clearance of less than or equal to 80 mL/min</criteria>
	<gender>All</gender>
	<minimum_age>10 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>August 2015</verification_date>
</DOC>